Accordingly, pharmacological stimulation of NCX1 with CN-PYB2 mitigates L-BMAA-induced neurotoxicity, supporting its potential as a novel therapeutic target for ALS [49]. This evidence concerns the gene SLC8A1 and amyotrophic lateral sclerosis.